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Introduction: Diagnosing non-small cell lung cancer on biopsy/
cellblock samples by morphology may be demanding. As sparing
material for molecular testing is mandatory, a minimalist immuno-
histochemistry (IHC)-based diagnostic approach is warranted by
means of novel, reliable, and easy-to-assess biomarkers.
Methods: Forty-six consecutive biopsy/cellblock samples and the
corresponding resection specimens (as the gold standard for mor-
phology and IHC) from 30 adenocarcinomas (AD), 10 squamous
carcinomas (SQC), 5 adenosquamous carcinomas (ADSQC), and 1
sarcomatoid carcinoma (SC) were IHC-evaluated for p40 [corre-
sponding to nontransactivating Np63 isoforms] and thyroid tran-
scription factor-1 (TTF1) by semiquantitative assessment. For p40,
also immunodecoration intensity was taken into account and dichot-
omized as strong or low.
Results: Nonrandom and overlapping distributions of the relevant
markers were found in biopsy/cellblock and surgical specimens,
which closely correlated with each other and the diverse tumor
categories, with no differences in area under curve-receiver-operat-
ing-characteristic curves for each marker between any two samples,
including p40 and p63. Diagnostic combinations were p40/
TTF1 or TTF1 for AD (where p40 was negative, apart from 5/30
AD showing at the best 1–2% tumor cells with low intensity);
p40/TTF1 (p40 strong and by far higher than 50%) for SQC; and
p40/TTF1 or p40/TTF1 (p40 strong and less than 50%) for
ADSQC. The single SC case was p40/TTF1, suggesting glan-
dular lineage. Practically, 41/46 (89%) tumors were correctly clas-
sified by IHC on small samples, including 30 AD, 10 SQC, 1/5
ADSQC, and no SC. Underdiagnosis of ADSQC was actually
because of sampling error of biopsies/cellblocks rather than insuf-
ficient biomarker robustness, whereas underdiagnosis of SC was
really because of the failure of either marker to highlight epithelial-
mesenchymal transition.
Conclusions: This minimalist IHC-based model of p40 and TTF1
on biopsy/cellblock samples was effective to correctly subtype most
cases of lung cancer.
Key Words: NSCLC, Morphology, Biopsy, Cellblock, Surgical
specimen, Immunohistochemistry, Diagnosis, TTF1, p40, p63.
(J Thorac Oncol. 2012;7: 281–290)
An emerging issue of the so-called therapeutic pathology1in lung cancer regards the precise subtyping of non-small
cell lung carcinomas (NSCLC),2 which may yet present a
difficult challenge by morphology alone when dealing with
limited material and/or poorly differentiated tumors.2–6 This
issue is relevant to clinics, when considering that more than
two-thirds of patients are still diagnosed late with locally
advanced or metastatic diseases, for whom tailored therapy
may be required.7 We recently have indicated that immuno-
histochemistry (IHC)-driven small biopsies paralleled ulti-
mate profiling and diagnoses on surgical specimens, paving
the way to its potential application to perspective clinical
trials too on lung cancer.8 A paradigm shift of the traditional
morphology-related approach on small cytology and/or bi-
opsy specimens5,9 has recently been incorporated into the
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new IASLC/ATS/ERS classification on lung adenocarcinoma
(AD), which recommends using IHC and/or multidisciplinary
setting to minimize the category NSCLC-not otherwise specified
(NOS) and sparing diagnostic material for predictive molecular
testing.9–11 Hence, a minimalist IHC algorithm approach based
on informative, reliable, reproducible, and easy-to-assess bio-
markers is warmly advisable for NSCLC to be typed for the sake
of clinical usefulness and tenability of costs.
We have hypothesized that, in small biopsy or cellblock
samples, a two-hit diagnostic model based on thyroid tran-
scription factor-1 (TTF1), a very popular and sensitive de-
tector of pulmonary AD12–16 and p40, a relatively poorly
known marker of squamous cell differentiation, either non-
neoplastic or tumoral, related to nontransactivating (non-TA),
truncated, or N isoforms of the p63 gene family of nuclear
transcription factors,17–19 could be helpful to better refine
NSCLC diagnoses. The p63 gene encodes diverse mRNA
isoforms, which are generated by the activity of two different
promoters, one of which internal to exon 3, which lead to the
accumulation of TAp63 isoforms acting as TA agents favor-
ing cell cycle arrest with apoptosis and cell differentiation
induction and/or Np63-p40 isoforms acting as negative
dominant agents, which stimulate cell proliferation and block
apoptosis with unrestrained tumor cell growth.20 In the nor-
mal lung tissue, by IHC, Np63-p40 is confined to the
nonterminal respiratory branch21 where it consistently deco-
rates the basal layer of the bronchial/bronchiolar epithelium
and the myoepithelial cells of the bronchial glands, whereas
TAp63 may be inconsistently expressed by type II pneumo-
cytes especially in areas of fibrosis and inflammation.22
Although TTF1 is also shared by other pulmonary
tumors, including neuroendocrine tumors,23–26 and, quite
rarely, nonpulmonary and nonthyroidal tumors,27 p40 expres-
sion in cancer is almost always confined to the squamous cell
carcinoma (SQC) domain, independently of the organ of
origin22,28–34 and the squamous cell component of adenosqua-
mous carcinoma (ADSQC) in the lung.34,35 Our previous
observation that lung AD could overexpress TA p63 but not
p40 isoforms at both the IHC and molecular levels (in
abstract form only)36 and that p40 was consistently negative
in fine-needle aspiration cytology samples of AD37 prompted
us to investigate in more detail the diagnostic implications of
the duet p40/TTF1 on a consecutive series of biopsy and
cellblock samples of NSCLC. We hypothesized that TTF1-
negative and/or strongly p63-expressing lung AD22,38 would
be a diagnostic dilemma in the event of poor differentiation or
inadequate morphology, so additional markers consistently
negative in AD (such as p40),36,37 through an innovative
algorithm, could prove to be useful tools in challenging cases.
The study was aimed at evaluating the effectiveness of
a novel, two-hit IHC model of p40 and TTF1 on limited
diagnostic material from 30 AD, 10 SQC, 5 ADSQC, and 1
sarcomatoid carcinoma (SC) to forecast the eventual diagno-
ses on surgical specimens according to the current lung
cancer classification.10,39 In particular, negativity for p40
always excluded by definition SQC and ADSQC and paved
the way to the likelihood of facing with AD also in the event
of TTF1 negativity. The epithelial-mesenchymal transition,
which is particularly developed in SC,40,41 was missed by
either marker.
MATERIALS AND METHODS
Patients and Tumors
A series of 46 consecutive preoperative NSCLC sam-
ples consisting of 24 fine needle aspiration biopsy cellblocks,
12 fiberoptic bronchoscopy or transcutaneous core biopsies of
pulmonary nodules, and 10 transcutaneous core biopsies of
regional lymph nodes from 30 males (range, 43–77 years)
and 16 females (range, 45–70 years), with the corresponding,
paired surgical specimens (31 lobectomies, 14 pneumonecto-
mies, and 1 atypical resection), were raised from the archives
of the Department of Pathology and Laboratory Medicine of
the IRCCS National Cancer Institute of Milan between 2006
and 2009. The lack of a previous history of cancer elsewhere
in the body before sampling was also required for entering the
investigation (approved by the institutional review board).
Twenty-nine of the 46 patients (63%) underwent histology-
guided neoadjuvant chemotherapy (CT) before radical sur-
gery. According to the seventh edition of the TNM staging
system,42 there were 4 tumors stage IA (2 CT), 4 IB (3 CT),
5 IIA (3 CT), 8 IIB (4 CT), 21 IIIA (15 CT), 3 IIIB (2 CT),
and 1 IV. All biopsies and surgical specimens had been fixed
in 4% buffered formaldehyde solution for 12 to 24 hours and
embedded in paraffin. No special stains were used to high-
light mucous deposition within tumor cells43,44 to test the
robustness of our minimalist IHC approach and also because
of a lower sensitivity rate of mucin stains in comparison with
IHC. All the original hematoxylin and eosin (H&E)-stained
sections of surgical specimens were blindly reviewed by two
experienced pathologists in lung cancer (G.P. and A.F.)
without knowledge of patients’ identity or original tumor
categorization according to the 2004 World Health Organi-
zation classification criteria on lung cancer,39 assuming that
these revised diagnoses made up the gold standard for any
comparison. No revision was planned on the original H&E-
stained sections of biopsies or cellblocks, inasmuch as the
main end point of the study was to verify whether and what
extent an innovative diagnostic approach based on the use of
two biomarkers only could faithfully parallel the correspond-
ing IHC profiles and, hence, eventual diagnoses on surgical
specimens. All tumors were categorized as much definitively
as possible, avoiding diagnosing NSCLC-NOS or large cell
carcinoma (LCC). In particular, ADSQC was defined by
morphology (concurrence of AD and SQC components, ei-
ther accounting for at least 10%),39 whereas SC was outlined
by the presence of sarcomatoid (giant and spindle cell)
elements accounting for at least 10%.39 Large cell neuroen-
docrine carcinoma was excluded by morphology and IHC of
appropriate pan-endocrine markers.39 So settled, the study
comprised 30 AD, 10 SQC, 5 ADSQC, and 1 SC. The
relatively higher proportion of ADSQC we observed in our
tumor series was likely to be related to the prevalence of
locally advanced stage and poorly differentiated tumors,
when considering that such tumors have been reportedly
associating with a particular propensity to give rise to local
and distant metastases and pursue a more aggressive clinical
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course compared with conventional lung carcinomas.45–47 No
tumor grading was tried on preoperative biopsy/cellblock
samples and the 29 patients undergoing preoperative CT,
whereas the remaining 17 chemonaive patients, including 9
AD, 6 SQC, and 2 ADSQC, showed all but 2 (1 G1 and 1 G2)
poorly differentiated tumors.
Immunohistochemical Evaluation
All tumor samples, either biopsy/cellblock or surgical,
were assessed for TTF1 (clones 8G7G3/1 and SPT24), p40
and p63, whereas the 5 ADSQC, 2 TTF1-negative AD, and
the case of SC were also characterized for napsin-A, surfac-
tant, cytokeratin 7 (CK7), cytokeratins 5/6 (CK5/6), desmo-
collin-3 (DSC-3), and vimentin to better unravel glandular
(napsin-A, CK7, and surfactant) or squamous (DSC-3 and
CK5/6) cell lineage or the epithelial-mesenchymal transition
(vimentin), as elsewhere detailed2,8,37,40,48,49 (Table 1).
Briefly, 3- to 4-m-thick sections were reacted for 30 min-
utes with the relevant antibodies and then incubated with a
commercially available detection kit (EnVision FLEX,
Dako, Glostrup, Denmark) following the manufacturer’s in-
structions and previously refined IHC methods.8 The speci-
ficity of all reactions was checked replacing the primary
antibody with a nonrelated mouse immunoglobulin at a com-
parable dilution or using normal serum alone. Positive and
negative controls were used as appropriate.
Immunoreactivity was rendered semiquantitatively on a
scale from negative to 5, taken into account the entire
tumor area on paraffin-blocked samples and cellular compart-
mentalization of antibodies (nuclear area for TTF1, p40 and
p63; cytoplasm domain for CK5/6, CK7, napsin-A and sur-
factant; and membrane/cytoplasm labeling for DSC-3). Tu-
mors were considered negative if staining was completely
absent in the relevant cells; 1 cases showed immunoreac-
tivity in up to 10% neoplastic cells, 2 cases in 11 to 25%
neoplastic cells, 3 cases in 26 to 50% neoplastic cells, 4
cases in 51 to 75% neoplastic cells, and 5 cases in 76 to
100% neoplastic cells. This choice was determined by the
need of minimizing variability in the slide assessment when
trying punctual percentages. For p40, also the intensity of
immunolabeling was taken into account, as strong if similar
to the internal control represented by bronchial/bronchiolar
basal cell layer or low if less intense than seen in the normal
internal control.
Statistical Analysis
Qualitative data were compared by Fisher exact test “t”
test, Stuart-Maxwell’s test of overall marginal homogeneity
(for square tables with 2 rows/columns), and McNemar’s
test of overall bias or directional change (comparing the
total frequency of cases above the main diagonal of the
data table with the total frequency of cases below the main
diagonal).50 Unsupervised and supervised hierarchic clus-
tering analysis was performed using Cluster 3.0 software
(http://www.eisenlab.org/eisen/) and visualized by using
Java TreeView (http://jtreeview.sourceforge.net). The de-
fining features of the diverse clusters corresponded to the
different IHC scores used for the relevant markers. Simi-
larity was measured using Spearman rank correlation met-
ric, and clustering was performed by centroid linkage. Con-
tingency analysis and relative mosaic plots were performed
by means of JMP IN software (SAS Institute, Inc., Cary, NC),
calculating p values through the likelihood ratio test. Mosaic
plots indicated graphically the percentage (expressed from 0
to 1) of patients belonging to the different clusters after
stratifying for the different tumor subtypes (AD, SQC,
ADSQC, and SC). The diagnostic performance of IHC on
both biopsy/cellblock samples and surgical specimens was
evaluated approaching receiver-operating characteristic
(ROC) analysis, comparing curves by Z-test.8,51 For all tests,
two-sided p values were taken into account, with a threshold
less than0.05 as being statistically significant.
RESULTS
In Table 2, the comparison between original diagno-
ses on biopsy/cellblock samples and surgical specimens is
shown. It emerged that 33 (72%) of original diagnoses had
been correctly classified by morphology on biopsy/cell-
block samples, whereas the remaining 13 (28%) tumors
had been classified as NSCLC-NOS or misdiagnosed as
either SQC or AD.
By IHC, unsupervised hierarchic analysis suggested a
nonrandom and overlapping distribution of the relevant mark-
TABLE 1. Antibody Panel Used in the Current Study
Antibodies Mono/Polyclonal Clone Source Dilution Pretreatment
TTF-1 m 8G7G3/1 DAKO, Glostrup, Denmark 1:2000 PTLink-EDTA for 30 min
TTF-1 m SPT24 Novocastra, Newcastle, United Kingdom 1:1600 PTLink-EDTA for 15 min
p63 m 4A4 DAKO, Glostrup, Denmark 1:200 PTLink-EDTA for 15 min
p40 p — Calbiochem, Darmstadt, Germany 1:3000 PTLink-EDTA for 30 min
Cytokeratins 5/6 m D5/16 B4 Invitrogen, Camarillo, CA 1:25 PTLink-EDTA for 30 min
Cytokeratin 7 m K 72.7 NeoMarkers, Fremont, CA 1:400 PTLink-EDTA for 15 min
Desmocollin-3 m Dsc3-U114 Progen, Heidelberg, Germany 1:100 PTLink-EDTA for 30 min
Napsin-A m IP64 Novocastra, Newcastle, United Kingdom 1:500 PTLink-EDTA for 30 min
Surfactant m PE-10 DAKO, Glostrup, Denmark 1:4000 PTLink-EDTA for 15 min
Vimentin m V9 DAKO, Glostrup, Denmark 1:50 PTLink-EDTA for 15 min
TTF, thyroid transcription factor.
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ers across the tumor series under evaluation (Figure 1A–C).
Supervised hierarchic analysis showed, in either type of
material, that AD were mostly positive for TTF1 and essen-
tially negative or at the best 1 score (up to 1–2% positive
cells in 5/30 cases) for p40, with p63 exhibiting 1 to 3
score, whereas SQC lacked TTF1 and presented with 4/5
score for both p40 and p63 (Figure 1B–D). ADSQC in turn
showed variable coexistence of AD- and SQC-related pro-
files, whereas the case of SC was negative for TTF1 and p40
and showed only focal (1 score) p63 immunoreactivity
(Figure 1B–D). Pairwise comparison of each marker between
any two samples by unsupervised (Figure 2A) and supervised
(Figure 2B) hierarchic clustering resulted in high correlation
coefficients, which ranged from 0.92 for p63 to 0.99 for p40
(Figure 2C). The very close and distinct relationship of the
clusters with the diverse tumor categories in either type of
material was also confirmed by mosaic plot analysis which
showed overlapping of the relevant tumor profiling (Figure
3A, B). ROC analysis showed that the values of the area under
curve were higher than 0.9 for each marker and relevant
diagnosis in both surgical specimens and biopsy/cellblock
samples (Figure 4A, B, respectively), with no significant
FIGURE 1. A–D, Hierarchic unsupervised (A, C) and supervised (B, D) clustering analyses of 46 tumors showing a nonrandom dis-
tribution of the relevant markers in both surgical specimens (A, B) and biopsy/cellblock samples (C, D). Unsupervised analysis identi-
fied the same tumor clusters in both SS (clusters 1-SS to 3-SS) and BS (clusters 1-BS to 3-BS). Tumor clustering for conventional his-
tology defined distinct profiles for AD (positivity or negativity for TTF1 with up to 1 score for p40 and 1 to 3 for p63), which
corresponded to clusters 1-SS/2-SS in SS and 1-BS/2-BS in BS, and for SQC (lack of TTF1 and 4 to 5 score for p40/p63), which
corresponded to cluster 3-SS in SS and 3-BS in BS. ADSQC showed variable coexistence of AD- and SQC-related profiles (B, D),
whereas the single case of SC was focally (1) immunoreactive for p63 only (SS, surgical specimens; BS, biopsy/cellblock samples;
AD, adenocarcinoma; SQC, squamous cell carcinoma; ADSQC, adenosquamous carcinoma; SC, sarcomatoid carcinoma).
TABLE 2. Original Diagnoses by Morphology on Biopsy/Cell Block Samples as a Function of Surgical Specimens
Diagnoses on Surgical
Specimens by Morphology
No. of Cases
(n  46)
Original Diagnoses on Biopsy/Cellblock Samples
Adenocarcinoma Squamous Cell Carcinoma NSCLC-NOS pa
Adenocarcinoma 30 25 1 4 5.2E-09
Squamous cell carcinoma 10 0 8 2
Adenosquamous carcinoma 5 3 1 1
Sarcomatoid carcinoma 1 0 0 1
a p value according to Fisher exact test “t” test.
NSCLC-NOS, non-small cell lung cancer not otherwise specified.
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differences after pairing the two types of samples (Supple-
mentary file 1, http://links.lww.com/JTO/A188).
The punctual distribution of the relevant markers in paired
biopsy/cellblock samples and surgical specimens according to
the semiquantitative IHC scoring system and some representa-
tive pictures taken from two cases of AD, either biopsy or
surgical specimen are shown in Supplementary file 2
(http://links.lww.com/JTO/A189) and Figure 5A–H, respec-
tively. In AD, p40 was mostly negative (Figure 5H) or detect-
able in a minority (5/30) of tumors as an erratic (1–2%), 1
score occurrence of stained tumor cells (Figure 5D) at variance
with p63 that was much more represented in the same cases
(Figure 5G–C). Moreover, p40 immunostaining intensity was
strong in SQC and squamous cell component of ADSQC in
comparison with the few AD showing p40 in 1 to 2% tumor
cells, where it was low respect to the internal positive control.
No differences were seen between any two paired tissue types
for all markers but p63 in AD, and TTF1 immunoreactivity was
similar in all but two AD by using either clone (Supplementary
file 2, http://links.lww.com/JTO/A189). In the normal lung tis-
sue, p40 was confined to the basal cell layer of bronchial/
bronchiolar epithelium (Figure 5D–H) and in myoepithelial cells
of the bronchial glands, whereas p63 could also be seen in
scattered type II pneumocytes especially in areas of nonspecific
pulmonary or subpleural fibrosis.
A diagnostic algorithm was then constructed on surgi-
cal specimens by crossing p40 and TTF1 according to either
positive or negative profile (Figure 6). In particular, 1
p40-scoring tumors (five cases, all AD) were regarded as
being essentially negative in the algorithm, whereas any
FIGURE 2. A–C, Pairwise compari-
son for each marker between any
two samples according to unsuper-
vised (A) and supervised (B) hierar-
chical clustering analyses. High co-
efficients of correlation (C) were
found for each marker between SS
and BS (SS, surgical specimens; BS,
biopsy/cell block samples; AD, ade-
nocarcinoma; SQC, squamous cell
carcinoma; ADSQC, adenosqua-
mous carcinoma; SC, sarcomatoid
carcinoma).
FIGURE 3. A, B, Mosaic plot dia-
grams (the more surface of varying
colored rectangles, the more
amount of cases in the different
tumor subsets) confirmed a close
and distinct relationship of the
clusters with the diverse tumor cat-
egories in surgical specimens (A)
and biopsies (B), (AD, adenocarci-
noma; SQC, squamous cell carci-
noma; ADSQC, adenosquamous
carcinoma; SC, sarcomatoid carci-
noma).
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TTF1 amount was assumed to point to glandular differenti-
ation. Hence, tumors with p40/TTF1 profile were all AD,
whereas the p40/TTF1 combination clustered around two
AD and the case of SC (featuring a pleomorphic carcinoma
composed of AD and spindle and giant cell carcinoma). The
p40/TTF1 profile featured SQC if p40 was by far higher
than 50% (75–100%), whereas the five ADSQC expressed
p40/TTF1 profile in two cases (p40  50%) and p40/
TTF1 profile in three cases (any amount for either marker,
with mutual exclusion in two cases and occurrence in the
same tumor cells in one case). By additional markers (Table
1), the five ADSQC exhibited immunoreactivity for CK7 (all
cases), napsin-A (two cases), and surfactant (two cases) in the
glandular component and for DSC-3 and CK5/6 in the squa-
mous cell component, whereas the two p40/TTF1 AD
expressed variably CK7 or CK5/6 but not vimentin, and the
case of SC was strongly and diffusely positive for vimentin
with variable reaction for CK7 and CK5/6.
Overall, 41/46 tumors (89%) were correctly classified by
IHC on biopsy/cellblocks in comparison with surgical speci-
mens, including all cases of AD and SQC but only one of the
five ADSQC and no case of SC (Table 3). The global figure of
IHC-driven diagnoses, however, could be brought to 45/46
(98%) by also adding the four remaining cases of ADSQC,
which featured an exclusive SQC (three cases: TTF1/p40,
with p40 50%) or AD (one case: TTF1/p40, with p40
1–2% tumor cells) component. Only SC actually escaped diag-
nostic recognition with p40/TTF1 duet. The sensitivity, speci-
ficity, and diagnostic accuracy rates of IHC on the biopsy/
cellblock samples are presented in Table 4.
DISCUSSION
A main issue of this article, just like an inspiring principle,
was to assess the validity of an IHC approach on biopsy/
cellblock samples to effectively forecast the corresponding pro-
filing and eventual diagnoses on surgical specimens when ap-
plying a novel two-hit, minimalist algorithm based on p40 and
TTF1 IHC to simultaneously spare time, economic resources,
and diagnostic material. Overall, our findings are in keeping
with previously refined diagnostic conclusions drawn by means
of a more extended immunohistochemical panel on an indepen-
dent cohort of NSCLC biopsy specimens.8 The hierarchic clus-
tering approach in light of the current lung cancer classifica-
tion,39 the area under curve-ROC curve analysis for each marker
and relevant diagnoses between the two types of samples, the
FIGURE 4. AUC-ROC analysis curves for each marker and relevant diagnosis are shown in both surgical specimens (A) and
small biopsies (B). The high values of the areas under curve (AUC) in both types of material documented the high perfor-
mance of IHC to correctly classify adenocarcinoma (heralded by TTF1, with clone 8G7G3/1 or SPT24) and squamous cell car-
cinoma (heralded by p40 and p63).
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high correlation coefficients after pairwise comparison for each
marker between any two samples, the lack of differences in the
immunoreactivity classes for the relevant markers when crossing
biopsy/cellblock samples and surgical specimens (Supplemen-
tary file 2, http://links.lww.com/JTO/A189), and the overlapping
mosaic plots between clusters and the diverse tumor categories
in either type of material were all proofs supporting the belief
that biopsy/cellblock samples were as reliable as surgical spec-
imens for this two-hit IHC approach to identify different tumor
categories, with particular reference for AD, SQC, and a subset
of ADSQC. Such a conclusion is worthwhile because it paves
the way to novel perspectives in clinical lung cancer trials too, in
which the diagnostic assessment carried out by IHC would have
the same and perhaps better relevance, reliability, and weight to
the patient clinical management as that obtained by morphology
alone, especially when considering the general accuracy of IHC
to discover diverse cell differentiation lineages in poorly differ-
entiated lung cancer.52 Although it is commonly said that clin-
ical trials have been essentially guided by morphology, the real
contribution of IHC is hard to split after this technique has
entered the daily diagnostic armamentarium of most patholo-
gists.53 To face the new scenario of dealing with lung cancer
diagnoses on limited material,5 the new AD classification by
IASLC/ATS/ERS has wisely proposed a stepwise methodology
to ultimately classify tumors for clinical purposes, in particular
suggesting a precise terminology when using morphology or
other diagnostic adjuncts10 (IHC and/or multidisciplinary set-
ting) on small-sized material. As poorly differentiated AD often
are associated with shorter survival, more advanced stage54–56
and increased KRAS mutations (an adverse pronosticator for
EGFR-based therapy),57 the way to ultimately identify these
FIGURE 5. A–H, Representative pictures from two cases of
adenocarcinoma (AD) from biopsy (A–D) or surgical (E–H)
specimen. AD cells invading a fragment of bronchial mucosa
as seen with hematoxylin and eosin (H&E)-stained sections
(A) were also immunoreactive for TTF1 (B) and p63 (C) but
not p40, except for an erratic and faint labeling of few tu-
mor cells (D). Similarly, another sample of poorly differenti-
ated AD with solid growth pattern (E) showed strong and
diffuse immunoreactivity for both TTF1 (F) and p63 (G) but
not p40 (H). Note in the panel C and D (right upper corner)
and H (left lower corner) the internal positive control for p63
or p40, which are represented by the normal basal cell layer
of the bronchial epithelium.
FIGURE 6. Diagnostic algorithm constructed starting from
p40 for predicting diverse diagnostic combinations on surgi-
cal specimens. Of the five p40/TTF1 or p40/
TTF1ADSQC, four were missed in biopsy/cellblock for the
exclusive presence of the squamous (three cases) or glandu-
lar (one case) component. In ADSQC samples, TTF1 and
p40 could be expressed within the same tumor cells or in
mutually exclusive elements (see text for detail). Additional
characterization of the two p40/TTF1AD for CK7, CK5/6,
napsin-A, surfactant and desmocollin-3 (DSC-3) confirmed
such a diagnosis, whereas the case of SC showed strong and
diffuse labeling for vimentin (AD, adenocarcinoma; SQC,
squamous cell carcinoma; ADSQC, adenosquamous carci-
noma; SC, sarcomatoid carcinoma).
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tumors remains crucial for therapy. Therefore, to validate our
diagnostic algorithm, we implemented the minimalist panel
approach only in those cases showing challenging or ambiguous
phenotypes (ADSQC with p40/TTF1 or p40/TTF1; AD
and SC with p40/TT1), paying particular attention not to
exhaust the diagnostic material risking eventual molecular study.
To this purpose, we would recommend staining gently with
hematoxylin all tissue fragments after fixation to recognize them
more easily inside tissue bags or inclusion cassettes and place
them accurately along the cut surface of the blocks before
trimming and immediately cutting a H&E section and five/six
additional unstained sections on polarized or any adhesive-
treated slides to carry out diagnostic IHC, if any, and subsequent
molecular study. Interestingly, we also successfully destined
negative IHC-stained sections to FISH or sequencing analysis, if
required, to maximize the concept of sparing material and
obtaining clinically useful results (data not shown). As p40 was
a polyclonal antibody (at variance with all the other antibodies
listed in Table 1), we used other commercially available detec-
tion kits (Dako Envision Flex and Ventana BenchMark XT
biomarker platform system) obtaining the same results in terms
of labeling pattern, staining intensity, or number of immunore-
active tumor cells (data not shown).
Although mixing cytoplasmic and nuclear markers (e.g.,
TTF1/DSC-3 or p63/napsin-A) into antibody cocktails could be
an adequate answer in terms of sensitivity and specificity of
reaction to reach valuable diagnostic results,2,37 the validation of
a minimalist IHC approach to use in challenging cases is
warranted especially to preserve tissue for further molecular
testing.9,10 The use of nuclear (p40 and TTF1) over cytoplasmic
markers for SQC (DSC-3)37 or AD (napsin-A)48,49 resulted
particularly advantageous in severely damaged and shrinkaged
areas of biopsies, where cytologic details were poor and residual
cytoplasmic decoration is difficult to evaluate. As morphology
remains a diagnostic cornerstone for a desirable use of only one
AD marker and one SQC marker in demanding cases,5,10,11 we
propound p40 as a more powerful diagnosticator than p63 (see
also Figure 5), which may be widely expressed in up to one-third
of lung AD.22,38,58,59 At variance with TTF1, p40 is diagnosti-
cally powerful and meaningful when looking at either positive or
negative profiles (Figure 6). Conversely, TTF1 is diagnostically
meaningful only if positive, whereas, whenever is negative in
the setting of poorly differentiated tumors, it may underline
diverse tumor subtypes, including SQC, AD, ADSQC, SC, and
even salivary gland-type tumors (Supplementary File 3,
http://links.lww.com/JTO/A190). We successfully identified all
cases of SQC and AD by crossing p40 and TTF1, whereas only
20% ADSQC and none SC were actually diagnosed because of
either sampling errors or failure of these marker to highlight
epithelial-mesenchymal transition,40,41,60 in turn faithfully mir-
rored by vimentin IHC.8 In our study, we categorized tumors as
much definitively as possible, avoiding diagnosing NSCLC-
NOS or LCC. As LCC probably results from poor differentia-
tion and/or tumor sampling incompleteness,2,61 we usually have
been sampling the entire tumor mass or, at least, one block per
centimeter in the largest size to discover at least focal and more
differentiated, conventional features of glandular or squamous
cell lineage (data not shown). However, even maintaining the
tumor category of LCC, the p40/TTF1 duet is likely to reliably
work by highlighting the underlying SQC or AD differentiation
on the basis of the diverse immunoreactivity profiles expressed
by tumor cells.
We here propound some simple and practical sugges-
tive comments for the interpretation of the diverse p40/TTF1
profiles depicted in Figure 6 (Supplementary File 4,
http://links.lww.com/JTO/A191) and also to confirm previ-
ously released considerations.2,8,62
TTF1 immunoreactivity points decidedly to AD differ-
entiation (any amount and distribution), provided that p40 is
essentially negative (1–2% p40-immunoreactive cells may be
observed in a minority of AD but this finding does not
contradict such a diagnosis) at variance with p63 that may be
TABLE 3. Correlation Between Immunohistochemical Diagnoses on Biopsies/Cellblocks and Morphology on Surgical Specimens
No. of Cases
(n  46)
Diagnosis on Biopsies/Cellblocks by Immunohistochemistry
paAdenocarcinoma Squamous Cell Carcinoma Adenosquamous Carcinoma
Diagnoses on surgical specimens
Adenocarcinoma 30 30 0 0 5.96E-12
Squamous cell carcinoma 10 0 10 0
Adenosquamous carcinoma 5 1b 3c 1
Sarcomatoid carcinoma 1 1 0 0
a p value according to Fisher exact test “t” test.
b Missing diagnosis of adenosquamous carcinoma for the exclusive presence of the glandular component in biopsy/cellblock samples.
c Missing diagnoses of adenosquamous carcinomas for the exclusive occurrence of the squamous cell component in biopsy/cellblock samples.
TABLE 4. Comparison of Immunostained Biopsy/Cellblock
Samples with Surgical Specimens
Imunostained Samples
on Biopsy/Cellblock
Samples vs. Surgical
Specimens
Sensitivity
(95% CI)
Specificity
(95% CI)
Diagnostic
Accuracy
(95% CI)
Adenocarcinoma 30/30 14/16 44/46
100 (88–100) 88 (62–98) 96 (85–99)
Squamous cell carcinoma 10/10 33/36 43/46
100 (69–100) 92 (78–98) 93 (82–99)
Adenosquamous carcinoma 1/5 41/41 42/46
20 (1–72) 100 (91–100) 91 (72–98)
Sarcomatoid carcinoma 0/1 45/45 45/46
0 (0–98) 100 (92–100) 98 (88–100)
IHC, immunohistochemistry; CI, confidence intervals.
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deceptively detected, even consistently in up to one-third of
AD58,59 (see also Figure 5). Interestingly, ALK-rearranged
AD are most often p63 positive63 but they lack p40 (Pelosi et
al., manuscript in preparation).
Diffuse and strong p40 expression excludes AD by
definition and greatly supports SQC diagnosis if the percent-
age of immunoreactive cells is by far greater than 50%
(usually 75–100%), provided that TTF1 is completely nega-
tive (otherwise think of the possibility of facing with ADSQC
and search for appropriate morphology). The immunostaining
intensity for p40 is strong in SQC and the squamous cell
component of ADSQC in comparison with p40-immunore-
active AD, where it is usually low relative to the internal
positive control.
ADSQC diagnosis is heralded by p40/TTF1 profile or
p40/TTF1 profile (with p40  50%). Sampling error rather
than biomarker robustness is likely to hamper the final recogni-
tion of ADSQC on both surgical specimens64 and biopsies/
cellblocks (as in our investigation). Coexistence of glandular and
squamous traits within the same tumor cells we observed in our
study was previously described in pulmonary65 or esophageal66
carcinomas to testify the possibility of “amphicrine” bipheno-
typic tumors. The relatively higher proportion of ADSQC39 may
be related to the huge prevalence (38/46 cases, 83%) of locally
advanced stage or metastatic tumors and of poorly differentiated
tumors (44/46 cases, 96%), when considering that ADSQC has
been reportedly associating with a particular propensity to give
rise to local and distant metastases and pursue an aggressive
clinical course.45–47 Furthermore, the ADSQC incidence seems
actually to be rising, in close parallel with a greater awareness
for composite tumors in the lung67 and the generalized increase
of epidemic pulmonary AD.39,64 Further study is needed on a
larger caseload of ADSQC to confirm these preliminary data.
Negativity for p40 and TTF1 does exclude by definition
SQC of whichever origin and suggests AD or SC (the latter
suggested even on biopsy whether vimentin is diffusely and
strongly positive in all tumor cells for full-blown epithelial-
mesenchymal transition at variance with poorly differentiated
NSCLC8), and also sarcoma, melanoma, or mesothelioma has
to be ruled out by appropriate, additional markers and clinical
working up.
Negativity for p40 and TTF1 plus lack of vimentin
excludes confidently SC, melanoma, sarcoma, and to some
extent mesothelioma, paving the way to the possibility of
facing with pulmonary AD or unsuspected metastases for
which a careful clinic integration is mandatory.
In conclusion, this article first provides evidence on the
diagnostic performance of a two-hit minimalist IHC approach
on biopsy/cellblock samples based on the duet p40/TTF1, for
which either positive or negative profiles are meaningful and
diagnostically helpful. In particular, we recommend relying
routinely on p40 rather than p6358,59 for subclassifying
NSCLC to avoid interpreting TTF1/p63 AD as belonging
to the category of SQC-component containing tumors.
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